Preliminary results of a European multicentre phase 1 study with Oncofid-P-B for the treatment of BCG unresponsive carcinoma in situ (CIS) of bladder at the end of 12 consecutive weeks intensive course and during ongoing monthly maintenance phase - R. Hurle; G. Guazzoni; P. Colombo; A. Santoro; O. De Cobelli; E. Di Trapani; G. Nohales; L. Carlos; R. Duran-Merino; M. Lazzeri (European Urology Open Science, 2020)